[CAS NO. 245075-84-7]  LR-90

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [245075-84-7]

Distributor
Catalog
AS412152
Brand
Arctom Scientific
CAS
245075-84-7

DESCRIPTION [245075-84-7]

Overview

MDL-
Molecular Weight709.57
Molecular FormulaC35H34Cl2N4O8
SMILESO=C(NC1=CC=C(C=C1)OC(C)(C)C(O)=O)NC(C(Cl)=C2)=CC=C2CC3=CC=C(C(Cl)=C3)NC(NC4=CC=C(C=C4)OC(C)(C)C(O)=O)=O

For research use only. We do not sell to patients.

Summary

LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes [1] . LR-90 is also used in the research of diabetic animal model [2] .


IC50 & Target

AGE [1]


In Vitro

LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours [1] .
LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours [1] .
LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [1]

Cell Line: THP-1 cells
Concentration: 0, 25, 50, 100, and 200 μM
Incubation Time: 24 hours
Result: Showed no cytotoxicity to THP-1 cells.

RT-PCR [1]

Cell Line: THP-1 cells
Concentration: 0, 25, 50, 100, and 200 μM
Incubation Time: One hour before S100b addition for 4 hours
Result: Dose-dependently inhibited mRNA expression of RAGE, MCP-1, COX-2, IP-10, and NOX2 stimulated with S100b.

In Vivo

LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats [2] .
LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ZDF rats (13 to 40 weeks) [2]
Dosage: 50 mg/L
Administration: P.O. for 27 weeks
Result: Significantly reduced plasma triacylglycerol and cholesterol by ∼55% and ∼30%, respectively. Modestly affected hyperglycaemia and blood pressure. Lowered the body weight.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 140.93 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.4093 mL 7.0465 mL 14.0930 mL
5 mM 0.2819 mL 1.4093 mL 2.8186 mL
10 mM 0.1409 mL 0.7047 mL 1.4093 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution

* All of the co-solvents are available by MCE.